Advances in Microfluidic‐Based Core@Shell Nanoparticles Fabrication for Cancer Applications

• Published in: Advanced healthcare materials 2024-09, Vol.13 (23), p.e2400946-n/a
• Main Authors: Almeida, Duarte R. S., Gil, João Ferreira, Guillot, Antonio José, Li, Jiachen, Pinto, Ricardo J. B., Santos, Hélder A., Gonçalves, Gil
• Format: Article
• Language: English
• Subjects: Biological effects; Biological properties; Cancer; Cancer therapies; Cisplatin; Continuous production; Drug delivery; Drug delivery systems; Microchannels; Microfluidics; multiphasic nanoparticles; Nanofabrication; nanomedicine; Nanoparticles; Nanotechnology; Plasmids; Side effects; siRNA; theragnostic microfluidics; Therapy; tumor targeting
• ISSN: 2192-2640; 2192-2659; 2192-2659
• DOI: 10.1002/adhm.202400946

Current research in cancer therapy focuses on personalized therapies, through nanotechnology‐based targeted drug delivery systems. Particularly, controlled drug release with nanoparticles (NPs) can be designed to safely transport various active agents, optimizing delivery to specific organs and tumors, minimizing side effects. The use of microfluidics (MFs) in this field has stood out against conventional methods by allowing precise control over parameters like size, structure, composition, and mechanical/biological properties of nanoscale carriers. This review compiles applications of microfluidics in the production of core‐shell NPs (CSNPs) for cancer therapy, discussing the versatility inherent in various microchannel and/or micromixer setups and showcasing how these setups can be utilized individually or in combination, as well as how this technology allows the development of new advances in more efficient and controlled fabrication of core‐shell nanoformulations. Recent biological studies have achieved an effective, safe, and controlled delivery of otherwise unreliable encapsulants such as small interfering RNA (siRNA), plasmid DNA (pDNA), and cisplatin as a result of precisely tuned fabrication of nanocarriers, showing that this technology is paving the way for innovative strategies in cancer therapy nanofabrication, characterized by continuous production and high reproducibility. Finally, this review analyzes the technical, biological, and technological limitations that currently prevent this technology from becoming the standard. Microfluidic (MF) devices may become standard for CSNP formulation in cancer therapy, allowing precise control over the properties of nanocarriers. Precise nanofabrication pushes the boundaries in clinical research, as otherwise unstable anticancer agents now become viable for clinical practice. Recent advances in MF technology, although extremely versatile and modulable, are still limited by low scalability and dedicated infrastructures.